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Localization of SPARC in developing, mature, and chronically SPARC (Secreted Protein Acidic and Rich in Cys-
injured human allograft kidneys. teine, osteonectin, BM-40) is a glycoprotein that binds
Background. The matricellular protein SPARC (secreted collagen. Its proposed biological functions have beenprotein acidic and rich in cysteine) is expressed during develop-
ascribed to its interactions with extracellular matrix, itsment, tissue remodeling and repair. It functions as an endoge-
nous inhibitor of cell proliferation, regulates angiogenesis, reg- interactions with specific cytokines and growth factors
ulates cell adhesion to extracellular matrix, binds cytokines such as platelet-derived growth factor (PDGF) and vas-
such as platelet derived growth factor and stimulates trans- cular endothelial growth factor (VEGF), and its abilityforming growth factor- (TGF-) production. This study de-
to modulate expression of transforming growth factor-scribes the expression of SPARC during human renal develop-
ment, in normal kidneys and during renal allograft rejection. (TGF-), its ability to inhibit cell proliferation, and its
Methods. A total of 60 renal specimens, including normal anti-adhesive properties with respect to some cell types
areas from tumor nephrectomies (N  24), fetal kidneys (N  in culture [1, 2]. Of particular interest are putative roles27) and explanted renal allografts (N 9), were included in the
for SPARC in organ development [3–5] and wound re-study. SPARC protein was localized by immunohistochemistry
using two different antibodies. On consecutive sections SPARC pair [2, 6], as studies have demonstrated that this mole-
mRNA was detected by in situ hybridization. cule promotes angiogenesis, as well as the deposition and
Results. In the normal adult kidney SPARC protein was ex- organization of extracellular matrix molecules includingpressed by visceral and parietal epithelial cells, collecting duct
several members of the collagen family [2, 3, 7]. Theepithelium (CD), urothelium, smooth muscle cells of muscular
arteries and focally in interstitial cells. During renal develop- mechanisms by which these processes occur are not well
ment immature glomeruli demonstrated a polarized SPARC understood. However, the crystal structure of two mod-
expression in visceral epithelial cells at their surface abutting ules of the SPARC molecule has been determined andthe capillary basement membranes. In the fully differentiated
key structural domains thought to be responsible forglomeruli the expression pattern mirrored that of the adult
kidney. Furthermore, SPARC was abundantly expressed by der- these activities have been defined [8, 9].
ivatives of the ureteric bud, and smooth muscle cells of arterial Mindful of these potentially important biological func-
walls. During chronic allograft rejection SPARC is expressed tions, our group and others have presented evidencein neointimal arterial smooth muscle cells, infiltrating inflam-
linking SPARC expression to glomerular and tubulo-matory cells as well as by interstitial myofibroblasts in areas
of interstitial fibrosis. SPARC mRNA synthesis detected by in interstitial injury in a variety of disease models in rodents,
situ hybridization mirrored these protein expression patterns. including chronic cyclosporine nephropathy, renal abla-
Conclusion. These studies co-localize SPARC to several sites tion, passive Heymann nephritis, diabetes, and the angio-of renal injury previously shown to be sites of PDGF B-chain
tensin II infusion model [10–14]. A common finding inexpression and/or activity. We speculate that SPARC could func-
tion as an accessory molecule in chronic PDGF-mediated scle- these models is that SPARC is expressed by the -smooth
rosing interstitial and vascular injury. SPARC localization to muscle actin expressing interstitial fibroblasts (“myofi-
glomerular epithelial cells corresponds to similar findings in broblasts”) that participate in tubulointerstitial injury,rodents, and may reflect its role in cell adhesion and /or regula-
and that SPARC expression is associated with collagention of cell shape.
I expression in such areas of injury. An important link
between SPARC expression and the deposition of extra-Key words: SPARC, podocyte, glomeruli, interstitium, fibroblasts,
smooth muscle cells, transplant rejection, fibrosis, renal development. cellular matrix is the induction of TGF-, a well de-
scribed key regulator of matrix deposition, by SPARCReceived for publication November 2, 2001
both in vitro and in vivo [7, 14].and in revised form June 7, 2002
Accepted for publication July 22, 2002 Up-regulated SPARC expression in glomerular epi-
thelial cells also has been linked to immunologically me- 2002 by the International Society of Nephrology
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diated injury such as passive Heymann nephritis [10]. noblotting of synthetic SPARC peptides. The epitope
recognized by this monoclonal IgG was found to requireTherefore, it is of interest to know where SPARC is ex-
pressed in the human kidney. In one broad survey of amino acids 5-23 of the mature protein [18]. MAB-2 is
a murine monoclonal IgG1 antibody directed againsthuman tissues, SPARC expression was localized to sev-
eral mesenchymal cell types, including fibrocytes and vas- human SPARC peptide 1.1 (peptide 1.1 spans amino
acids 3 to 23 of SPARC) [15].cular smooth cells, but more specific localization of
SPARC expression within individual organs was not de- Smooth muscle cell marker. Murine monoclonal anti-
body 1A4 (Dako Corp., Carpinteria, CA, USA) has beentailed [15]. In the present study, we have employed im-
munohistochemical and in situ hybridization techniques characterized by tissue immunohistochemistry and West-
ern blotting and has been previously demonstrated toto localize SPARC protein and mRNA in developing,
mature, and chronically injured human allograft kidneys. recognize smooth muscle -actin in methyl Carnoy’s-
fixed tissues of human kidney [19–21].These studies demonstrate an association between SPARC
expression and fibrosing renal injury, extending the ob- Monocyte/macrophage marker. A murine monoclonal
antibody PG-M1 (Dako) directed against the CD68 epi-servations previously made in rodent systems to humans.
tope of human monocytes and macrophages was used
in methyl Carnoy’s-fixed tissues [22]. This antibody has
METHODS
been shown to recognize cells of monocyte/macrophage
Tissue lineage in fixed tissues with no loss of sensitivity com-
pared with frozen tissue specimens [22]. The specificityNormal human renal tissue (N  24) was obtained
from kidneys surgically excised because of the presence of this antibody has been established by studies of trans-
fected and untransfected cell lines and by immunocyto-of a localized neoplasm. Tissues utilized for this study
were obtained from macroscopically normal portions of chemical surveys of numerous cell lines and examples
of neoplastic and non-neoplastic hematopoietic tissues,kidney located at some distance from the neoplastic pro-
cess. Allograft kidneys (N  9) excised for irreversible as previously described [22].
PDGF A. Anti-PDGF A chain (Santa Cruz Biotech-rejection were used as an example of inflammatory and
advanced fibrosis injury. Human fetal kidneys (N  27) nology, Santa Cruz, CA, USA) is an affinity-purified rab-
bit polyclonal antibody raised against a 30 amino acidwere obtained from tissue examined after therapeutic
abortions. peptide corresponding to the amino terminus of the hu-
man PDGF-A chain. It has been characterized by West-Tissues were fixed in methyl Carnoy’s fixative (60%
methanol, 30% chloroform, 10% acetic acid) or in 10% ern blot and peptide absorption [23] and its specificity
demonstrated in human kidneys [23, 24].neutral buffered formalin for at least 12 hours, processed,
paraffin embedded and sectioned using conventional PDGF B. Murine monoclonal antibody PG7-007 (pro-
vided by Mochida Pharmaceutical, Tokyo, Japan) hastechniques. Some tissues from the nephrectomy speci-
mens also were snap frozen and utilized for RNA prepa- been characterized by Western blotting of whole kidney
extracts [24] and has been previously shown to specifi-ration.
These studies were performed under approval from cally recognize PDGF-B chain in methyl Carnoy’s fixed
tissue [21, 24].the University of Washington Human Subjects Division
(Approval #01-8008-E-01) under conditions of tissue an- PDGF-receptor. Anti-PDGF-receptor (A951; Santa
Cruz Biotechnology) is an affinity-purified rabbit poly-onymization, whereby all study investigators remain
masked to the specific identity of patients from whom clonal antibody. This antibody has been characterized by
Western blotting [25] and has been shown to specificallytissue sections were obtained. Accordingly, parameters
of clinical outcome related to SPARC expression could immunolabel PDGF -receptor in methyl Carnoy’s fixed
tissue [25, 26].not be evaluated.
Antibodies Western blotting
Western blotting was performed using lysates fromSPARC. Anti-SPARC (AON-5031) is a murine mono-
clonal antibody directed against human, rat, and bovine whole human kidneys or recombinant SPARC protein.
Lysates were fractionated on a 12% polyacrylamide elec-SPARC/osteonectin (Haematologic Technologies, Es-
sex Junction, VT, USA). This antibody was characterized trophoretic gel that contained 0.1% SDS and then trans-
ferred onto nitrocellulose membranes by electroblotting.by Western immunoblotting of purified, recombinant hu-
man SPARC [16, 17]. Specific immunoreaction was local- The blots were blocked with 5% bovine serum albumin
(BSA) in phosphate buffered saline (PBS) for one hourized to a 33 kD band of the non-glycoslyated recombi-
nant protein and a 43 kD band in tissue [12]. Epitope at 37C and then incubated with 0.2 to 2 g/mL of SPARC
(AON-5031) antibody or an equal concentration of nor-mapping of this antibody was achieved by enzyme-linked
immunosorbent assay (ELISA) and peptide dot-immu- mal rabbit IgG diluted in PBS containing 0.1% BSA for
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two hours at room temperature. After washing, the blots merase chain reaction (PCR). Total RNA was extracted
from snap frozen, normal human kidney tissue with TRIwere incubated with alkaline phosphatase conjugated
horse-anti-mouse IgG antibody (Vector Labs, Burlin- Reagent (MRC, Inc., Cincinnati, OH, USA), followed
by precipitation with isopropanol. First strand cDNAgame, CA, USA) for one hour. The blots were then vis-
ualized with 5-bromo-4-chloro-3-indolylphosphate and was synthesized from RNA by Moloney murine leuke-
mia virus reverse transcriptase (M-MLV RT; Gibco BRL,nitro blue tetrazolium (BCIP/NBT).
Gaithersburg, MD, USA) using either random hexamer
Immunohistochemistry primers or the SPARC 3 primer. The reaction mixture
consisted of 50 mmol/L Tris-HCl (pH 8.3), 75 mmol/LImmunohistochemistry was performed on methyl Car-
noy’s fixed, paraffin-embedded tissues following a stan- KCl, 10 mmol/L dithiothreitol (DTT), 3 mmol/L MgCl2,
1 U RNase inhibitor, 1 g RNA, 1 mmol/L 4dNTP, 200dard avidin-biotin complex (ABC) method, as previously
described in detail [20, 27]. Briefly, sections were depar- ng primer and 20 units of M-MLV RT in a total volume
of 20 L. The reactions were allowed to proceed for 45affinized in xylene and rehydrated in graded ethanols.
Endogenous peroxidase was blocked by incubation in minutes at 37C and then the enzyme was inactivated
by incubation at 65C for five minutes.3% hydrogen peroxide and non-specific binding was
blocked by incubation in 10% normal goat serum. The The synthesized first strand cDNA from the RT reac-
tion was amplified by PCR. The reaction mixture con-sections were then incubated for one hour with the pri-
mary antibody. Following washes in PBS, the sections tained 60 pmol of each primer, 10 mmol/L Tris-HCl,
1.5 mmol/L MgCl2, 500 mmol/L KCl, and 200 mol/Lwere sequentially incubated with biotinylated second an-
tibodies (Vector Labs), the ABC-Elite reagent (Vector 4dNTP. The PCR reactions were performed using a PTC
100 (MJ Research, Inc., Watertown, MA, USA) temper-Labs) and finally 3,3-diaminobenzidine (with nickel chlo-
ride enhancement) was used as the chromogen. The sec- ature cycler. After a five minute incubation at 85C,
2.5 U Taq DNA polymerase (Boehringer Mannheim,tions were counterstained with methyl green, dehydrated
and cover slipped. Indianapolis IN, USA) were added to each tube, fol-
lowed by a denaturation step at 94C for one minute, anSpecificity controls for the labeling procedures in-
cluded substitution of irrelevant non-immune mouse IgG annealing step at 64C for one minute and an extension
step at 72C for one minute. The reaction tubes wereor rabbit sera for the primary antibodies, and pre-absorp-
tion of the antibody with recombinant protein (for AON- then cycled 35 times for thirty seconds at 94C, followed
by one minute at 64C and one minute at 72C. After a5031), followed by the otherwise identical immunocyto-
chemical procedures. final extension step at 72C for ten minutes, the tubes
were held at 4C. A 10 L aliquot of the PCR products
Double label immunohistochemistry was fractionated on a 1% agarose gel, stained with ethid-
ium bromide and visualized with an ultraviolet transillu-Slides were first immunostained as described above
using MAB-2 or CD68 and DAB without nickel chloride minator. The expected 427 bp product was obtained from
two different RNA preparations using both the randomenhancement to visualize either SPARC or monocytes/
macrophages, respectively, with a brown reaction prod- hexamer primer and the 3 SPARC primer.
Probe preparation. The product from the PCR reac-uct. Following a PBS rinse and further block with 3%
hydrogen peroxide, the slides were incubated sequen- tion was cloned using the pGEM-T Vector System (Pro-
mega, Madison, WI, USA). The ligation reaction mix-tially with 1A4 or MAB-2 (to localize alpha smooth
muscle actin or SPARC, respectively) overnight at 4C, ture contained 2 Weiss Units of T4 DNA Ligase, 50 ng
pGEM-T Vector DNA, 30 mmol/L Tris-HCl (pH 7.5),HRP conjugated anti-mouse antibody (Dako, Carpin-
teria, CA, USA) and then developed with the True Blue 10 mmol/L MgCl2, 10 mmol/L DTT, 1 mmol/L adenosine
5-triphosphate (ATP) and 25 ng SPARC PCR productsubstrate (Kirkegaard & Perry Laboratories, Gaithers-
burg, MD, USA) to give a blue color reaction. DNA. The reaction was incubated for two hours at 15C
and then transformed into Maximum Efficiency DH5
In situ hybridization competent E. coli cells (Gibco BRL). After plating on
LB/amp/IPTG/X-gal plates, white colonies were selectedPrimer design. Two oligonucleotide primers were de-
signed to be used for the amplification of human SPARC. and used in a standard plasmid miniprep procedure.
After restriction enzyme mapping, one clone was se-The 3 primer (5-GGAGAGGTACCCGTCAATGG-3)
spans the eighth intron/exon junction (bases 374-395) of lected as it contained a single insert of the SPARC
cDNA. The presence of the insert was confirmed bythe human SPARC cDNA and the 5 primer (5-CGA
GTTTGAGAAGGTGTGCAGC-3) spans the fifth in- dideoxy sequencing of both strands from the T7 and
SP6 promoters of the pGEM-T vector. This constructtron/exon junction (bases782-801). The primers were syn-
thesized by Bio-Synthesis, Inc. (Lewisville, TX, USA). was linearized and transcribed into a riboprobe using
reagents from Promega (Madison, WI, USA), exceptRNA preparation, reverse transcription (RT) and poly-
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[35S]-uridine triphosphate (UTP), which was obtained dried, it was dipped in NTB2 nuclear emulsion (Eastman
Kodak, Rochester, NY, USA) and exposed in the darkfrom New England Nuclear (Boston, MA, USA). The
transcription reaction mixture contained 1 g of SPARC at 4C for two weeks. After developing, the sections were
counterstained with hematoxylin and eosin, dehydrated,cDNA (sense or anti-sense), 250 Ci of [35S]-UTP, 500
mol/L each of ATP, cytidine 5-triphosphate (CTP) mounted and viewed. Positive cellular labeling was de-
fined as five or more silver grains concentrated over aand guanosine 5-triphosphate (GTP), 40 U of RNAsin,
10 mmol/L DTT, 40 mmol/L Tris-HCl and 10 U of T7 single cell.
In addition, non-radioactive in situ hybridization waspolymerase. After 75 minutes at 37C, the template DNA
was digested by adding 1 U of DNAse (Promega) and performed. The slides were prepared as above and the hy-
bridization was carried out using a digoxigenen-labeled ri-incubating at 37C for an additional 15 minutes. Free
nucleotides were separated with a Sephadex G-50 col- boprobe (Boehringer Mannheim, Indianapolis, IN, USA).
The slides were washed as above and the probe was de-umn. Probes were used within 48 hours.
Sequencing of probe and verification of identity. One tected using horseradish peroxidase labeled anti-digoxi-
genin antibody (Boehringer Mannheim), followed by am-nanogram of the insert DNA cDNA fragment of the
human SPARC/pGEM-T plasmid was characterized by plification using the TSA-Indirect Kit (NEN) and then
DAB with nickel enhancement to give a black reactionTaq polymerase dye terminator cycle sequencing (Perkin
Elmer Corporation, Foster City, CA, USA). Annealing product. The slides were then counterstained with methyl
green and cover slipped.of template to oligonucleotide primers was achieved
through the use of SP6 and T7 primers specific for the
PGEM-T plasmid. Both strands of the insert were com-
RESULTS
pletely sequenced. This SPARC DNA cDNA fragment,
Histologic characterization of renal tissuesobtained from the uninvolved kidney tissue of a single
patient with a localized neoplasm, was found to be 427 Developing kidneys were obtained from fetuses of
estimated 57 to 120 days gestational age, as previouslybp in length. The fragment was 99% identical (423/427
bp) with the coding region of human SPARC cDNA described. These kidneys demonstrated age appropriate
features of glomerulogenesis and tubulogenesis, and(accession #Y00755 and #J03040). The lack of complete
identity was due to differences at the position of the uniformly lacked features of maldevelopment such as
dysplasia, scarring, or cyst development. Mature renalwobble base of 4 codons. These differences were found
in exon 8 and correspond to the following amino acids: tissues obtained from nephrectomy specimens demon-
strated focal changes typically associated with aging, in-#183, CAT (His) to CAC (His); #190, GAG (Glu) to
GAC (Glu); #212, TTC (Phe) to TTT (Phe); and #213, cluding focal global glomerulosclerosis involving less
than 10% of glomeruli sampled, mild patchy interstitialCCT (Pro) to CCC (Pro). The insert of this recombinant
plasmid corresponds to amino acids 85 through 226 of fibrosis and associated tubular atrophy, and focal mild
intimal sclerosis involving muscular arteries. Pathologicthe human SPARC protein sequence.
In situ hybridization. Fetal and adult kidney tissue features characteristic of other specific glomerular, tubu-
lointerstitial, or vascular injuries were not identified inthat had been fixed in 10% formalin and embedded in
paraffin was deparaffinized following standard protocol. this sample. Kidneys with chronic allograft nephropathy
demonstrated more extensive global glomerulosclerosis,The sections were washed with 0.5 standard saline ci-
trate (SSC; 1 SSC  150 mmol/L NaCl, 15 mmol/L Na and some demonstrated variable, focal, and generally
mild features of transplant glomerulopathy as detectedcitrate, pH 7.0) and digested with proteinase K (1g/mL;
Sigma Chemical Co., St. Louis, MO, USA) in Tris-Cl by histological examination. Features of transplant glom-
erulopathy included increased glomerular lobularity,buffer (500 mmol/L NaCl, 10 mmol/L Tris, pH 8.0) for
40 minutes at 37C. Several 0.5 SSC washes were fol- thickening and splitting of peripheral capillary walls, and
mesangial expansion. These changes were clearly presentlowed by prehybridization for two hours in 50 L of
prehybridization buffer (0.3 mol/L NaCl, 20 mmol/L Tris in four out of nine allograft nephrectomies, and were
equivocally present in three additional kidneys in thispH 8.0, 5 mmol/L EDTA, 1 Denhardt’s solution, 10%
dextran sulfate, 10 mmol/L DTT). The hybridizations group. Allograft kidneys demonstrated somewhat dif-
fuse fibrosis of the cortical interstitium, associated withwere started by adding 500,000 cpm of 35S-labeled ribo-
probe in 50 L of prehybridization buffer and allowed to frequent and focally prominent infiltrates of mononu-
clear leukocytes in the interstitium. Muscular arteriesproceed overnight at 50C. After hybridization, sections
were washed with 0.5 SSC, treated with RNase A (20 demonstrated marked, typically concentric thickening of
the intima by accumulations of matrix and spindleg/mL, 30 min at room temperature), washed in 2 SSC
(2  2 min), followed by three high-stringency washes shaped cells. In several cases, there were additional fea-
tures of superimposed acute rejection characterized byin 0.1 SSC/0.1% Tween 20 (Sigma) at 50C, and several
2 SSC washes. After the tissue was dehydrated and air infiltration of the subendothelial space by mononuclear
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Fig. 1. Characterization of the anti SPARC
antibody and SPARC expression in normal
renal tissue (A) Western blot of recombinant
SPARC protein using the monoclonal antibody
AON-5031. (B) Immunohistochemistry with
the anti-SPARC antibody AON-5031 shows
staining of myocytes of the arterial wall. (C )
This staining is abolished after preincubation
with recombinant SPARC protein (original
magnification200) (B, C, D, E ) Immunohis-
tochemistry for SPARC using the monoclonal
antibody MAB-2 on mature kidney tissue as
part of a tumor nephrectomy specimen (B, C,
40; D 400; E-G, 600 original magnifica-
tions). (D) In the normal adult glomerulus,
SPARC expression was usually restricted to
visceral (arrow) and parietal epithelium (ar-
rowhead). Myocytes of the arterial wall, as
well as endothelial cells, constitutively express
SPARC as do periarterial adventitial fibro-
blasts (E). (F ) Illustrates SPARC expression
in collecting ducts. (G ) Focal SPARC expres-
sion was detected in interstitial cells (arrow).
leukocytes, presumably due to diminished immunosup- recombinant protein (Fig. 1A) and to a 43 kD band in
tissue [12]. Incubation with recombinant protein abol-pression prior to anticipated allograft nephrectomy.
ished the staining by immunohistochemistry (Fig. 1 B, C).
Characterization of the antibodies and SPARC MAB-2 is a murine monoclonal IgG1 antibody directed
expression in normal adult kidneys against SPARC peptide 1.1 (acids 3 to 23 of SPARC)
[28]. Both antibodies resulted in comparable stainingDuring the establishment of SPARC immunohisto-
patterns in methyl Carnoy’s fixed, paraffin embeddedchemistry we tested two antibodies against SPARC. The
tissue sections. The staining pattern with the monoclonalmurine monoclonal antibody directed against human,
antibody MAB-2 was slightly superior to the results ob-rat, and bovine SPARC/osteonectin (AON-5031; Hae-
matologic Technologies) antibody was characterized by tained with AON-5031. MAB-2 demonstrated a higher
sensitivity and a lower background, as compared to AON-Western immunoblotting of purified, recombinant hu-
man SPARC (Fig. 1A) [16, 17]. Specific immunoreaction 5031. These differences were especially apparent in vas-
cular smooth muscle cells and glomerular visceral epithe-was localized to a 33 kD band of the non-glycoslyated
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Fig. 2. SPARC mRNA expression in the nor-
mal adult kidney. In situ hybridization on ma-
ture kidney tissue as part of a tumor nephrec-
tomy specimen, using SPARC sense (A) and
SPARC antisense probes (B–E, all orig.400).
(A) The tissue section that was hybridized
with the sense riboprobe illustrates the low
number of non-specifically deposited silver
grains. (B) Strong SPARC mRNA expression
was detectable in adult glomeruli with an ac-
centuation of silver grains in the peripheral
glomerular tuft over visceral (arrow) and pari-
etal (arrowhead) epithelial cells. (C) Scat-
tered interstitial cells were SPARC positive
(arrow). (D) SPARC mRNA expression by
tubular epithelial cells, most likely collecting
duct epithelium. Note the localization of
mRNA to the endothelium of a peritubular
capillary (arrow). (E) Arteriosclerotic artery,
which demonstrated SPARC mRNA in the
neointima (arrowhead).
lial cells. The detection of SPARC expression in intersti- In the mature adult kidney (Figs. 1 and 2), SPARC is
uniformly expressed by glomerular visceral epithelialtial cells and collecting ducts was similar when either of
the two antibodies was utilized. Four different lots of cells and very commonly in parietal epithelial cells (Figs.
1D and 2B). In the vasculature, arterial smooth muscleantibody AON-5031 were obtained from the manufac-
turer, and noticeable lot-to-lot differences in sensitivity cells (Figs. 1E and 2E), adventitial fibroblasts, and col-
lecting duct cells demonstrated widespread SPARC ex-in immunohistochemical studies of the same tissue were
observed. Overall, the combined immunoreactive prop- pression (Figs. 1F and 2D). Focal expression of SPARC
was detected in distal tubular epithelium. Neointimalerties of AON-5031 and MAB-2 and the correlative lo-
calization of mRNA by in situ hybridization solidify the smooth muscle cells, routinely encountered in the arte-
riosclerosis of aging human kidneys, also demonstratedvalidity of these reagents as tools for localization of
SPARC in human tissues. For these reasons, we relied on expression of SPARC (Fig. 2E). SPARC-expressing en-
dothelial cells were common in large and medium sizedantibody MAB-2 for the principal findings of this study.
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Fig. 3. SPARC protein expression in the de-
veloping kidney. Immunohistochemistry for
SPARC using the monoclonal antibody MAB-2
on sections of human fetal kidneys (A, B, C,
E orig.400; D orig.600). (A) In well differ-
entiated glomeruli, visceral epithelial cells
were uniformly SPARC positive, commonly
with a diffusely stained cytoplasm around the
unstained nuclei. (B) In earlier stages of glo-
merular development, SPARC staining be-
came detectable at the base of the visceral epi-
thelial cells (arrowhead). (C) Collecting ducts
were uniformly SPARC positive with a promi-
nent polarization toward the luminal surface
and a weaker staining on the abluminal side.
(D) Peritubular interstitial cells were com-
monly found to express SPARC. (E) Vascular
smooth muscle cells uniformly expressed
SPARC (compare to Fig. 1E).
arteries, whereas glomerular endothelium was not stained prising the visceral and parietal epithelium of developing
for SPARC (Fig. 1 D, E, and Fig. 2D). Interstitial fibro- glomeruli (Fig. 3 A, B). In earlier glomerular structures
blasts in the uninjured kidney were usually only weakly SPARC commonly became apparent in a polarized dis-
and focally SPARC positive by our immunohistochemi- tribution at the base of immature, columnar appearing
cal techniques (Figs. 1G and 2C). There was possible focal podocytes, where they attach to the capillary basement
staining of peritubular capillary endothelium, but we could membranes (Fig. 3B). During glomerular maturation the
not achieve sufficient resolution by light microscopy to pattern changed toward the diffuse cytoplasmic pattern
exclude localization of SPARC in adjacent interstitial fi-
seen in adult visceral epithelial cells (Figs. 3A and 1D).broblasts. The protein expression mirrored the mRNA
Expression of SPARC by mesangial cells in differenti-expression detected by in situ hybridization (Figs. 1 and 2).
ated glomeruli was identified in 8 of 21 kidneys. Although
SPARC expression during renal development these structures often failed to demonstrate immuno-
histochemically detectable SPARC expression, SPARCSPARC expression in developing glomeruli was most
prominent at late stages of differentiation of cells com- also was expressed focally by differentiating epithelial
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cells comprising comma- and S-shaped bodies in about 4C, there were rare instances of possible SPARC expres-
sion by glomerular endothelial cells.half of the cases. There was no evidence of SPARC expres-
sion by structures involved in earlier stages of nephro- Figure 6 illustrates glomerular expression of SPARC
and members of the PDGF ligand/receptor family in glo-genesis such as metanephric blastema, tips of ureteric
buds, or condensing vesicles. meruli from a renal allograft with chronic allograft ne-
phropathy. Particularly noteworthy is the colocalizationSPARC was expressed in each of the extraglomerular
tissue compartments in the fetal kidney (Fig. 3). Tubular of SPARC and PDGF A chain in visceral epithelial cells;
PDGF B chain expression is confined to the mesangium.expression of SPARC was generally confined to differen-
tiated cells of the collecting duct system and pelvic uro- Figure 7 illustrates SPARC and PDGF expression in an
artery with features of acute and chronic rejection, inthelium (Fig. 3 C, D). In these sites, SPARC protein
appeared polarized with localization primarily at the lu- which SPARC expression by medial and neointimal
smooth muscle cells (expressing  smooth muscle actin)minal surface of these cells. The basolateral cell surface
at times also demonstrated localized expression of SPARC is congruent with PDGF A chain expression and in which
SPARC expression by endothelial cells and some infil-(Fig. 3C). Medial smooth muscle cells of arteries demon-
strated widespread expression (Fig. 3E). Prominent ex- trating leukocytes is congruent with expression by PDGF
B-chain and PDGF receptor by these cells.pression of SPARC by the adventitial fibroblast-like cells
adjacent to muscular arteries also was identified. In the
interstitium, SPARC was widely expressed by mesenchy-
DISCUSSION
mal cells likely corresponding to interstitial fibroblasts
This study localized the expression of both SPARCboth within the cortex and medulla (Fig. 3D). As in adult
protein and mRNA to glomeruli, collecting ducts, uro-kidney, sites of SPARC protein expression were coinci-
thelium, interstitial cells, and arteries of developing asdent with sites of SPARC mRNA synthesis as detected
well as mature human kidneys. These sites of SPARCby in situ hybridization (data not shown).
expression in humans generally, but not invariably, con-
form to previous observations obtained from rodentSPARC expression during human renal
allograft rejection models of renal injury [10, 11, 13, 29]. Some differ-
ences with a prior published study localizing SPARC inIn chronic allograft nephropathy, a prominent change
human kidney were apparent in the present investiga-in SPARC expression became apparent. Noteworthy in
tion. Mundlos et al described SPARC expression onlythis set of tissues was the prominent expression of
in glomeruli in fetal human kidneys [30]. This stands inSPARC in the neointima of arteries with histologic fea-
contrast to the findings of SPARC expression in collect-tures of chronic rejection (obliterative arteriopathy; Fig.
ing ducts, urothelium, arteries, and interstitial cells re-4 A, B). Expression of SPARC by smooth muscle cells
ported here. Our findings were made both on proteinof the medial portions of the arterial wall persisted (Fig.
and mRNA level and conform to findings in other mam-4 A, B). An increased number of SPARC positive inter-
malian systems (for example, rat and mouse) as well asstitial cells became detectable in areas of interstitial fi-
to general observations in human fibrocytes and arterialbrosis (Fig. 4E). The distribution pattern in the intersti-
cells reported by Porter et al [15]. The reagents utilizedtium mirrored the distribution of smooth muscle actin
both for in situ hybridization and immunocytochemistrypositive interstitial myofibroblasts (compare Fig. 4 pan-
in the study of Mundlos et al are distinct from thoseels E and F), which was further evidenced by double im-
utilized in our own study, and this may account for muchmunolabeling of these cells for actin and SPARC as il-
of the difference. It is possible their reagents lacked thelustrated in Figure 5. At sites of interstitial leukocytic
sensitivity to detect extraglomerular expression.infiltrates, a high number of SPARC positive cells were
In the human glomerulus, the localization of constitu-scattered between infiltrating inflammatory cells. How-
tive expression of SPARC to visceral epithelial cells isever, a minority of interstitial leukocytes, expressing the
of interest in view of the anti-proliferative properties ofmonocyte/macrophage differentiation marker CD68, could
this molecule for cells in vitro. There is increasing evi-be shown on replicate tissue sections to express SPARC
dence that the glomerular visceral epithelial cell has anpeptide as detected by immunohistochemistry (Fig. 5).
extremely limited capacity for replication [31, 32]. There-Additionally, endothelium of peritubular capillaries
fore, SPARC may contribute to the resistance to prolifer-commonly demonstrated SPARC expression, especially
ative stimuli in these cells. It is also of interest that wein areas of interstitial fibrosis (Fig. 4D). A small subset of
have previously localized PDGF A-chain expression toinflammatory cells, typically seen in lumina of peritubu-
the human glomerular visceral epithelial cell [23]. A rolelar capillaries, also expressed SPARC. Glomerular epi-
for SPARC in mediating renal injury as well as injurythelial cells demonstrated persistent expression of SPARC
in other tissues is suggested in part by its ability to bindwithout clear change in its expression by other compo-
nents of the glomerular tufts. As illustrated in Figure the growth factor PDGF and hence modulate signaling
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Fig. 4. SPARC expression in transplant
nephrectomies. Immunohistochemistry for
SPARC (A200; C400; D, E600 origi-
nal magnification) and for smooth muscle
actin (B 200; F 400 original magnifica-
tion) performed on sections from explanted
transplants. (A) Prominent neointima forma-
tion with a principal component of SPARC
positive cells. (B) The distribution of smooth
muscle actin in an artery from the specimen
illustrated in panel A. (C) Transplant glom-
erulopathy, with persistent expression of
SPARC by visceral epithelial cells (compare
to Fig. 1D). Uncommonly, there appeared
to be expression of SPARC by cells on both
sides of the glomerular basement mem-
brane (arrow), which could represent focal
expression by glomerular endothelium or
possibly an unusual sectioning artifact. (D)
Several peritubular capillaries with SPARC
expression by endothelium, here associated
with the presence of intraluminal leuko-
cytes (cross section: arrow, longitudinal sec-
tion: arrowhead). (E) SPARC-expressing
interstitial cells were present at sites of in-
terstitial fibrosis. (F) Expression of smooth
muscle actin by myofibroblasts in the inter-
stitium. The pattern mirrored the expres-
sion pattern of SPARC (compare panel E
from a different specimen).
pathways regulated by this factor. However, the binding modulate the ability of PDGF-BB and PDGF-AB to
interact with this receptor by virtue of its binding to theof SPARC to PDGF is thought to occur via the PDGF
B-chain, and thus would affect only activities of the PDGF B-chain molecule [33]. We speculate that SPARC
may modulate the response of parietal epithelial cells toPDGF heterodimers PDGF-BB and PDGF-AB, but not
the PDGF-AA or PDGF A-chain per se [33]. Therefore, PDGF in glomerular injury, but a means to test this
hypothesis in human cells is not currently available.we are uncertain whether any biological interaction re-
sults from the co-localization of these two molecules. Mesangial expression of SPARC has been documented
in the rodent both in vivo and in vitro. In rat mesangialThe current study also demonstrates that SPARC is
constitutively expressed by parietal epithelial cells, a cell cells, SPARC expression may be up-regulated by several
growth factors including PDGF and FGF-2 [12]. In turn,type previously shown by us and others to be one in which
constitutive expression of PDGF receptor  (PDGFR) its up-regulated expression by mesangial cells has been
correlated with resolution of the acute mesangial cellis found [34]. This is of particular interest in view of
the studies by Raines et al, showing that SPARC can proliferation that occurs in the anti-Thy-1 mesangial pro-
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Fig. 5. Double immunolabeling of cortex from an allograft nephrectomy for expression of SPARC and the monocyte/macrophage marker CD68
in A, B and C and SPARC and -smooth muscle actin in D. (A) SPARC (blue label) is expressed by arterial endothelial cells (arrows), smooth
muscle cells of the vessel wall (arrowheads) and scattered cells in the tubulointerstitium, some of which also may express CD68 (brown label),
although this is equivocal. There is no CD68 expression by vascular or tubular cells, but expression is confined to interstitial leukocytes. (B) Same
case and labeling as panel A. High power view demonstrates expression of SPARC (blue) by some CD68 positive interstitial monocytes/macrophages
(arrows). (C) Area of marked inflammation in the interstitium in which there are scattered CD68 positive monocytes/macrophages, a minority of
which also express SPARC (blue) (arrows). (D) SPARC (brown) is expressed by arterial endothelium and medial smooth muscle cells (arrows).
These smooth muscle cells also express -smooth muscle actin (blue).
liferative glomerulonephritis model [12]. This is consis- each of these molecules typically is down-regulated in
the healthy mature kidney, but may be re-expressed intent with the observation that cultured mesenchymal cells,
including mesangial cells, from SPARC deficient mice the course of mesangial proliferative injury and repair.
This has suggested a paradigm where the biologic eventsexhibit increased rates of cell proliferation [35]. Again, it
has been proposed that the association between SPARC and the molecular signals that direct these events occur-
ring in the repair of glomerular injury represent a reca-expression and resolution of mesangial cell proliferation
in the anti-Thy-1 model may reflect possible interruption pitulation of renal development [37]. The expression of
SPARC has not yet been tested in human glomerulo-of binding of PDGF B-chain to its receptors, an event
that mediates earlier phases of injury in this model. This nephritis to evaluate whether this paradigm holds for
this molecule as well. The evidence concerning SPARCstudy demonstrates that SPARC is occasionally expressed
by human mesangial cells, most notably in the fetal kid- expression obtained from the anti-Thy-1 mesangial pro-
liferative nephritis model indicates that the paradigm isney. Our work and that of others has previously identi-
fied several molecules such as -actin, PDGFR, PDGF true at least in the rat. We show in Figure 7 that, at least
in chronic allograft nephropathy, mesangial expressionB-chain, and p75 nerve growth factor receptor, that are
expressed by mesangial cells at the same stages of devel- of PDGF B-chain may be up-regulated while glomerular
SPARC expression remains confined to visceral epithe-opment identified for SPARC [21, 36]. Expression of
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Fig. 6. Expression of SPARC (A, B), PDGF-
B chain (C, D), PDGF A-chain (E, F ) and
PDGF -receptor (G, H ) in glomeruli in
serial tissue sections from an allograft ne-
phrectomy. A, C, E and G are from glomer-
uli with some features of transplant glo-
merulopathy (thickened capillary walls,
increased lobularity), and B, D, F and H
are from a glomerulus undergoing sclerosis.
There is persistent expression of SPARC
and PDGF A chain in visceral epithelial
cells, a feature of normal mature kidneys.
PDGF B is expressed in the mesangium and
in tubulointerstitial cells. There is no expres-
sion of PDGF -receptor by intrinsic cells of
the glomerular tuft. Immunohistochemical
analysis of PDGF -receptor could not be
accomplished for technical reasons.
lial cells, similar to the expression pattern of PDGF some infiltrating inflammatory cells in areas of chronic
fibrosing injury occurring as part of chronic allograftA-chain. Moreover, the autocrine loop effected by SPARC
on cultured mesangial cells, via its induction of TGF-1 nephropathy. SPARC expression by interstitial cells is
only focally and weakly detectable in the mature adultand collagen type I, is likely to prove significant in fibro-
proliferative disorders of the glomerulus [6, 7]. kidney, but in the setting of chronic tubulointerstitial
injury, this expression is dramatically up-regulated. Se-The second major finding of this study is the localiza-
tion of SPARC to interstitial myofibroblast-like cells and rial labeling studies and double immunolabeling studies
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Fig. 7. Serial sections of a typical injured ar-
tery in a case of chronic allograft nephropathy.
SPARC (A) and PDGF A-chain (C ) are uni-
formly expressed by smooth muscle cells of
the medial layer of the vessel wall and in the
neointima. SPARC also is expressed by endo-
thelial cells and likely some infiltrating leuko-
cytes in the subendothelial lining, similar to
expression patterns of PDGF B-chain (illus-
trated in B) and PDGF -receptor (illustrated
in D). Expression of -smooth muscle actin
by smooth muscle cells of the medial compart-
ment of the artery wall and neointima (illus-
trated in E ) is identical to that of the majority
of SPARC expressing cells in this vessel.
demonstrated that most SPARC-expressing interstitial in chronic injury states may modulate the effects of con-
tinued exposure to PDGF by these cells, either throughcells also express-smooth muscle actin. This last feature
has led to consideration of these interstitial cells as myo- direct anti-proliferative properties of SPARC or by the
direct interference with the binding of PDGF to its recep-fibroblasts [38–41]. Accumulation of these cells has been
clearly identified at sites of human and experimental tors. The induction of TGF- by SPARC might be an-
other important pathway involved in the regulation oftubulointerstitial injury, and there is recent evidence that
their enumeration may be a particularly accurate prog- tubulointerstitial fibrosis [14].
SPARC was localized also to a minority of the infil-nostic factor in studies of human diseases such as diabetes
mellitus [41, 42] and membranous nephropathy [43]. It trating mononuclear leukocytes typically present in areas
of chronic tubulointerstitial injury occurring as part ofis also of note that these myofibroblast-like interstitial
cells in the human express both PDGF  and  receptors chronic allograft nephropathy. SPARC previously has
been identified in monocytes/macrophages in wound heal-[25, 44], making them likely to be responsive to stimula-
tion by heterodimers containing the PDGF B-chain. In- ing in experimental systems. However, the specific activi-
ties of leukocyte SPARC are not currently understood.deed, Tang et al have demonstrated direct stimulation of
proliferation and collagen production by myofibroblast- SPARC has been shown to mediate some responses of
human monocytes to injury, such as the production oflike renal interstitial cells in rats in vivo exposed to infu-
sions of PDGF B-chain [45]. In this site, it seems likely matrix metalloproteinases [46]. This suggests the possi-
bility of an autocrine stimulatory pathway for these ef-that up-regulated SPARC production by interstitial cells
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in renal interstitial fibrosis and in renal vascular injury. Kidney Intfector cells, which are commonly present in various renal
50:1978–1989, 1996
diseases. 12. Pichler RH, Bassuk JA, Hugo C, et al: SPARC is expressed by
mesangial cells in experimental mesangial proliferative nephritisStudies of SPARC deficient mice have shown that
and inhibits platelet-derived-growth-factor-medicated mesangialexpression of SPARC is not a requirement for normal
cell proliferation in vitro. Am J Pathol 148:1153–1167, 1996
development of murine kidneys [47], but the putative 13. Gilbert RE, McNally PG, Cox A, et al: SPARC gene expression
is reduced in early diabetes-related kidney growth. Kidney Int 48:biologic activities of this molecule have not been ade-
1216–1225, 1995quately tested in renal disease settings in these mice.
14. Bassuk JA, Pichler R, Rothmier JD, et al: Induction of TGF-
Our current study suggests roles for SPARC in human beta1 by the matricellular protein SPARC in a rat model of glomer-
ulonephritis. Kidney Int 57:117–128, 2000renal development and fibrosing renal tubulointerstitial
15. Porter PL, Sage EH, Lane TF, et al: Distribution of SPARC inand vascular injuries. Our findings are consistent with a normal and neoplastic human tissue. J Histochem Cytochem 43:
hypothesis that the effects exerted by SPARC in these 791–800, 1995
16. Bassuk JA, Braun LP, Motamed K, et al: Renaturation of SPARCinjury processes are at least in part the result of modifi-
expressed in Escherichia coli requires isomerization of disulfidecation of signaling through PDGF ligand/receptor path- bonds for recovery of biological activity. Int J Biochem Cell Biol
ways, but the findings in humans and experimental injury 28:1031–1043, 1996
17. Bassuk JA, Baneyx F, Vernon RB, et al: Expression of biologicallysystems have not yet provided a proof of this possibility.
active human SPARC in Escherichia coli. Arch Biochem Biophys
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